/
We are a pharmaceutical company committed to transforming the treatment of endocrine diseases and endocrine-related tumors through science rooted in patient needs. We are focused on discovering, developing, and commercializing novel therapies, with a core expertise in targeting GPCRs with small molecules that have specifically tailored pharmacology and properties.
The business is unprofitable at the operating level (-6714.77% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue up 640.7% YoY with margins expanding 25898.7pp.
ROIC dropped from -27.21% to -33.78%, capital efficiency is deteriorating. Negative free cash flow of -$384M. The business is consuming cash, not generating it.
Profitability & Returns
Revenue (TTM)
$18M
▲ +640.7% YoY
Net Income (TTM)
-$496M
▼ -55.9% YoY
Op. Margin
-3020.32%
▲ +25898.7pp YoY
ROIC
-36.60%
▼ -6.6pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$420M
▼ -63.9% YoY
Op. Cash Flow (TTM)
-$414M
▼ -64.2% YoY
Net Debt
-$1.24B
Net Cash Position
Cash & Equiv.
$1.29B
5Y CAGR: +155.3%
Continue Research